Regorafinib Plus Avelumab Provides Long-Term Benefit in Some Patients With GIST
Combination treatment with avelumab and regorafenib has shown activity in patients with relapsed/refractory gastrointestinal stromal tumors.
Source: oncologynurseadvisor.com